These 300(+) Biotech Twit­ter cit­i­zens are the quick­est to tweet news


Like many of you, I have a com­pli­cat­ed re­la­tion­ship with Twit­ter. I don’t feel good at it, but here I am ob­sess­ing over it. I re­sent feel­ing like I need to be good at it. That’s a bad way to feel about a re­la­tion­ship you’ve been in for sev­en years.

Your friends have more friends than you do — this is the rub of so­cial net­work­ing. There isn’t a pro­fes­sion­al I know who is proud of the small size of their Rolodex. It’s no won­der so many in bio­phar­ma join Twit­ter on­ly to aban­don it af­ter a few tweets. The de­fault state of their new ac­count ad­ver­tis­es to the world that no­body at all fol­lows what you have to say. That doesn’t feel good ei­ther.

If you work in­side bio­phar­ma, I’ll ad­mit there’s not much rea­son for you to post to Twit­ter. Yes, there are ex­cep­tions and many en­joy a rich­er ca­reer as a re­sult. But it’s not true for a big ma­jor­i­ty. Most knowl­edge in bio­phar­ma is held in the minds and ex­pe­ri­ences of peo­ple and com­pa­nies. These are not shared in pub­lic.

The beau­ty of Twit­ter is that you don’t have to say any­thing at all.

Read-on­ly Twit­ter

The dirty se­cret of Twit­ter is that it’s de­pen­dent on jour­nal­ists and pro­fes­sion­al con­tent-cre­ators. We go to Face­book to see time­lines of our friends and fam­i­ly. LinkedIn time­lines on­ly mat­ter if you’re on a job hunt or re­cruit­ing peo­ple your­self.

Se­ri­ous news hounds turn to Twit­ter be­cause it’s the on­ly se­ri­ous place to craft a hard news time­line. And it turns out “read-on­ly Twit­ter” is quite an amaz­ing prod­uct. When you tune in­to the con­ver­sa­tions of oth­ers, you learn things you didn’t know you need­ed to know.

Jour­nal­ists, brands, and bots all rush to post con­tent the mo­ment it’s fit for con­sump­tion. Some links have legs, oth­ers don’t. It’s an op­er­at­ing sys­tem for the dis­sem­i­na­tion of news and the meta-com­men­tary that fol­lows. This is the top of the pub­lic in­fo pyra­mid. From here these things fil­ter down­stream to the 80% of the in­dus­try who have no re­la­tion­ship with Twit­ter.

Plug­ging your ear in­to the top of this nerve cen­ter gets you clos­er and faster to this in­for­ma­tion. Whether this in­for­ma­tion is good or bad, that’s for you to de­cide. Like the tele­phone game, where you tell some­one some­thing and it changes down­stream, your in­for­ma­tion is pur­er the clos­er it was to the sig­nal. It’s with­out the col­or. No ana­log degra­da­tion.

Too much noise

Hav­ing asym­met­ric in­for­ma­tion is a huge ad­van­tage in busi­ness, right? You know some­thing some­body else doesn’t, and they don’t have ac­cess to those bit of in­fo. This is how it worked in 1990.

In 2016 you can pos­sess asym­met­ric in­for­ma­tion that’s freely avail­able to all, but was lost in the dig­i­tal ether of tweets, press re­leas­es, al­go­spam, and Na­tive Ӓd­ver­tis­ing. In­for­ma­tion is eas­i­ly buried in the con­tent swamp. You just can’t see it all.

Now there’s plen­ty of firms who’ll charge a $10,000 month­ly re­tain­er to sift through these tweets, trav­el ob­scure parts of the web, trav­el be­hind the pay­walls, send you a sum­ma­ry, make sure things don’t fall through the cracks. A few lucky bio­phar­ma ex­ec­u­tives en­joy these perks.

What if you’re brand new to bio­phar­ma? How about if you’re a sea­soned vet but just new to Twit­ter? How do you know who to fol­low? Twit­ter for all in­tents and pur­pos­es is a con­sumer brand. De­spite it be­ing a rich, im­me­di­ate source of in­for­ma­tion for drug de­vel­op­ers, Twit­ter the com­pa­ny has no prod­ucts to on­board such a niche au­di­ence.

We love Twit­ter at End­points and want more peo­ple in bio­phar­ma to en­joy the ben­e­fits of it — even as a pro­fes­sion­al lurk­er.

In­tro­duc­ing Mar­co, our news­bot

Last Au­gust we qui­et­ly launched our vi­ral news­bot@endpts. We re­cent­ly named it Mar­co — con­stant­ly ex­plor­ing BioTwit­ter.

It’s job is to:

  • Search for links in every tweet made in a known uni­verse of thou­sands of BioTwit­ter ac­counts;
  • Cal­cu­late the ve­loc­i­ty of each link shared;
  • If a link starts mov­ing much faster rel­a­tive to oth­er links, it’s now trend­ing;
    • Mar­co then vis­its the link it­self and ex­tracts the head­line, au­thor, and source. We want our own, in­de­pen­dent in­for­ma­tion about the link.
  • Mar­co then tweets the link. It gives cred­it with a hat tip [h/t] to the ac­count that it saw tweet the link first.

It’s that last part that forms the ba­sis of this spe­cial re­port: who was the first per­son to re­port this news?

Mar­co has been read­ing BioTwit­ter 24 hours a day, 7 days a week for al­most a a year now. Over this time we can ag­gre­gate the hat tips Mar­co doled out and come up with this ex­act list.

We guar­an­tee if you fol­low a healthy seg­ment of this list — you’re plugged in­to to heart of the link econ­o­my on BioTwit­ter.

What this list is not

Any­time you rank your friends and col­leagues there’s bound to be hard feel­ings. So let me state for the record:

  • This is not a list of the best ac­counts to fol­low in BioTwit­ter. Many tweeps nev­er post links and in­stead con­tribute with con­text and analy­sis. Mar­co is a few tech­no­log­i­cal rev­o­lu­tions away from be­ing able to un­der­stand when some­one is be­ing sar­cas­tic or help­ful, so it ig­nores text-on­ly tweets. And that’s of­ten the best part of Twit­ter.
  • This is not a who’s who list. There are plen­ty of those around and none of them do any­thing for the per­son who sim­ply wants to be the best pro­fes­sion­al lurk­er on BioTwit­ter.
  • There are no val­ue judge­ments here. This is a pure­ly da­ta-dri­ven list. Yes, it’s our own pro­pri­ety da­ta and I’m not like­ly to di­vulge the ex­act man­ner in which we re­duce the fire­hose of BioTwit­ter in­to a trick­le. But we’re pre­sent­ing the da­ta as-is.


Biotech Twit­ter cit­i­zens most fre­quent­ly cred­it­ed with post­ing trend­ing links first

Over 100 hat tips
John­Cendpts
Fierce­Biotech
Bio­S­tocks
brad­lon­car
Andy­Biotech
adamfeuer­stein
matthe­wher­p­er
phar­malot
Er­ic­Topol
Ben­the­Fi­dler
Fier­cePhar­ma

 

50 – 99 hat tips
Derek­lowe
megtir­rell
Ja­cob­Pli­eth
Mav­er­ick­NY
cru­sadernz
Scrip­Don­naDC
Bos­Biz­Don
ld­tim­mer­man
busi­ness
jonathanrock­off
Reuters_Health
3NT
CGrantWSJ
ste­faniei
LifeSciVC

 

20 – 49 hat tips
Arm­strong­Drew
BioRunUp
reuters­Ben­Hir
Biotech­World
John_LaMat­ti­na
Na­ture­News
car­dio­brief
Lof­tus
an­to­niore­gal­a­do
Jean­neWhalen
ivanoran­sky
Zachary­Bren­nan
Car­o­lineYLChen
AKAarsalan
Emi­ly­W­Fierce
DShay­witz
Black­Swan­Phar­ma
Wrigley­Tom
kris­ten_hal­lam
GideonGil
Bio­DueDili­gence
Reuters­Biz
Car­ly­H­Fierce
WSJbusi­ness
phar­magos­sip
TST­biotech
jq1234t
scrip­news
ZTrac­er
alexlash
ar­lenewein­traub
IPOtweet
WS­JA­sia
bio_clouse­au
FDALawyers
NPRHealth
ByJon­Gard­ner
charlesorn­stein
FDAad­comm
cafephar­ma
PDRen­nert
WSJ
lisam­jarvis
edy­ong209
NE­JM
ju­liaoftoron­to
rplenge
denis­eroland
lo­mu_j

 

At least 10 hat tips
techre­view
Boston­Globe
Reuters
pk­noepfler
WSJhealth
Lau­ra­LandroWSJ
porte­feuille­fun
El­y­se­Tanouye
sdbn
an­drew_ward1
TomBur­ton­WSJ
Ac­tivist­Shorts
Fay­Cortez
Biotech­News
dg­macarthur
dr­bachin­sky
Na­ture­Biotech
zbiotech
cells_nnm
Fes­tivus159
iito­Life­Science
skathire
medtech_ma
US_FDA
genen­tech
DewDili­gence
RNA­i­An­a­lyst
cray­ton_h
FT
vox­dot­com
Scrip­Mandy
car­lz­im­mer
vir­gini­ahugh­es
dhovekamp42
Alec­Gaffney
NYTHealth
PhilSer­afi­no
hmkyale
steveus­din1
fdalaw­blog
The­At­lantic
Scot­tKirsner
IAmBiotech
stem­cel­las­says
TheStal­wart
Trade­Hawk
Bio­Break­out
an­naed­ney
politi­co
ddi­a­mond
sxbe­gle
Frank_S_David
CMichael­Gib­son
Mogu­lAzam
Dr­MiguelPerales
ScripEleanor
Bio­Cen­tu­ry
brentl­saun­ders
rleu­ty_biotech
michael_mezher
ProP­ub­li­ca
rick­berke
Gan­tosJ
Dan­Bud­wick
Phar­ma­ceu­ticBen
FierceMed­Dev
sci­en­tre
srq­s­tock­pick­er
CN­BC

 

At least 4 hat tips
joe­walk­er­WSJ
ethanjweiss
23alo­ha
forbeshealth
GlobeR­obW
EMA_News
sci­ences­can­ner
Ope­nOut­crier
Mike­Huck­man
big3bio­BOS
davies­bj
Mer­ck
mt­md­phd
Drchik23
Med­ical­News
SA_Health­In­vest
db­sable
dan­pri­mack
an­naw­math­ews
guardian­science
Med­ical­New­sUSA
taralach
eval­u­atephar­ma
Ram­sey_Bagh­da­di
westr
ze­ro­hedge
Liq­uid_Biop­sy
Lin_ling_88
dsobek
Ai­ims1742
DrAD­Kline
JNapo­dano
BioWorld
LizSz­abo
BI_Sci­ence
TechCrunch
US­ATO­DAY
not­So­JunkD­NA
ideaphar­ma
Mar­tin­Shkre­li
Evavon­Schaper
mau­reen­m­far­rell
Car­olynyjohn­son
BioTerp
cb­tad­vi­sors
bm­snews
Al­ny­lam
at­ti­cusMB
fund­Duchenne
SashaDamouni
Tim­mer­man­Re­port
bbchealth
bmj_lat­est
Fier­cePhar­mA­sia
biotech­day
FDA_Drug_In­fo
Prop­Thinker
No­var­tis­S­cience
matt_levine
blsuth
FDA­Me­dia
News­from­Science
Sud­han­vaRaj
FiveThir­tyEight
vlad33301
dami­an­garde
BlinkX90
sandiego­science
Mykalt45
Adam­Singer
ScottGot­tlieb­MD
Don­WNi­chol­son
Grady­For­rer
AS­CO
Davi­dAStein­berg
RPM­Re­port­Mike
sloan_ket­ter­ing
Hum­bleBio­Trad­er
JA­MA_cur­rent
Chillz­Trad­ing
SueD­Hell­mann
jay­brad­ner
daph­ne­zo­har
Vikas­Dan­dekarET
cd­weaver
bh­munos
SIRF_Re­port
mslopat­to
michaelscal­ly
michael_gilman
Dougal­lan1
prince­tongb
Drug­Patent­Watch
chris­sy­farr
Za­ck­foot
ma­ki_ki­ta­mu­ra
jfli­er
Life­SciencesMkt
wilbanks
He­len­Bran­swell
afrakt
rt­narch
Ogut_Ozgur
aman­dam­ick­lus
walidgel­lad
smhedge­cock
iBo­nanos
PearlF
jtozz
maryn­m­ck
Dr­Jen­Gunter
Boston_Biotech
broad­in­sti­tute
ES­chat­tner
pi­car­don­health
ScripLu­cie
can­cer­doc­NYC
Xcon­o­my
No­var­tis
hrana
BioWriter­Chik
Nick­PaulTay­lor
WHO
phar­ma­con­nect
myger­sh­berg
gau­tamkol­lu
An­a­lyst­Wire
Econ­SciTech
EP­Clin­i­cal­Tri­al
Bio­Med­Track­er
pe­ter­bach­md
Caulfield­Tim
Mar­i­lyn­Mann
John_Hemp­ton
mbeisen
John­PLeonard­MD
charles_ga­ba
aleszuba­jak
Black­Hawk­Trad­er
JCM­c­Crack­en
Break­ingNews
jodi­gral­nick
eye­onf­da
Robert­Langreth
berna­tolle
cel­lec­tis
Kathy­Giusti
RS_Flinn
Arthur­Ca­plan
bertha­coombs
Lym­phoma_Doc
aaronecar­roll
NIH
NYTScience
Street_In­sid­er
David­Ju­urlink
Na­tRevDrugDisc
ac­taest­fab­u­laXX
23Chromz
EP­Van­tage
Fast­Com­pa­ny
Mau­riceOn­TW
An­nemarieVtW
biotech­baumer
ewan­bir­ney
Jack­West­MD
On­col­o­gy­Times
at­lasven­ture
JPZaragoza1
BioWino
RNA_Biotech
John­Tuck­er­PhD
Col­fax­Cap­i­tal
si­mon­bay­ly
NBC­New­sHealth
fw­phar­ma
In­natePhar­ma
Er­icP­Fierce
thinkgenome
AC­In­vestor­Blog
AlpineBV_Miller
HaertlG
Scrip­Mike­Ward
Roche
at­ul­butte
Na­tureMed­i­cine

Is a pow­er­house Mer­ck team prepar­ing to leap past Roche — and leave Gilead and Bris­tol My­ers be­hind — in the race to TIG­IT dom­i­na­tion?

Roche caused quite a stir at ASCO with its first look at some positive — but not so impressive — data for their combination of Tecentriq with their anti-TIGIT drug tiragolumab. But some analysts believe that Merck is positioned to make a bid — soon — for the lead in the race to a second-wave combo immuno-oncology approach with its own ambitious early-stage program tied to a dominant Keytruda.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Fangliang Zhang, AP Images

UP­DAT­ED: Leg­end fetch­es $424 mil­lion, emerges as biggest win­ner yet in pan­dem­ic IPO boom as shares soar

Amid a flurry of splashy pandemic IPOs, a J&J-partnered Chinese biotech has emerged with one of the largest public raises in biotech history.

Legend Biotech, the Nanjing-based CAR-T developer, has raised $424 million on NASDAQ. The biotech had originally filed for a still-hefty $350 million, based on a range of $18-$20, but managed to fetch $23 per share, allowing them to well-eclipse the massive raises from companies like Allogene, Juno, Galapagos, though they’ll still fall a few dollars short of Moderna’s record-setting $600 million raise from 2018.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

As it hap­pened: A bid­ding war for an an­tibi­ot­ic mak­er in a mar­ket that has rav­aged its peers

In a bewildering twist to the long-suffering market for antibiotics — there has actually been a bidding war for an antibiotic company: Tetraphase.

It all started back in March, when the maker of Xerava (an FDA approved therapy for complicated intra-abdominal infections) said it had received an offer from AcelRx for an all-stock deal valued at $14.4 million.

The offer was well-timed. Xerava was approved in 2018, four years after Tetraphase posted its first batch of pivotal trial data, and sales were nowhere near where they needed to be in order for the company to keep its head above water.

Drug man­u­fac­tur­ing gi­ant Lon­za taps Roche/phar­ma ‘rein­ven­tion’ vet as its new CEO

Lonza chairman Albert Baehny took his time headhunting a new CEO for the company, making it absolutely clear he wanted a Big Pharma or biotech CEO with a good long track record in the business for the top spot. In the end, he went with the gold standard, turning to Roche’s ranks to recruit Pierre-Alain Ruffieux for the job.

Ruffieux, a member of the pharma leadership team at Roche, spent close to 5 years at the company. But like a small army of manufacturing execs, he gained much of his experience at the other Big Pharma in Basel, remaining at Novartis for 12 years before expanding his horizons.

Covid-19 roundup: Ab­b­Vie jumps in­to Covid-19 an­ti­body hunt; As­traZeneca shoots for 2B dos­es of Ox­ford vac­cine — with $750M from CEPI, Gavi

Another Big Pharma is entering the Covid-19 antibody hunt.

AbbVie has announced a collaboration with the Netherlands’ Utrecht University and Erasmus Medical Center and the Chinese-Dutch biotech Harbour Biomed to develop a neutralizing antibody that can treat Covid-19. The antibody, called 47D11, was discovered by AbbVie’s three partners, and AbbVie will support early preclinical work, while preparing for later preclinical and clinical development. Researchers described the antibody in Nature Communications last month.

Pfiz­er’s Doug Gior­dano has $500M — and some ad­vice — to of­fer a cer­tain breed of 'break­through' biotech

So let’s say you’re running a cutting-edge, clinical-stage biotech, probably public, but not necessarily so, which could see some big advantages teaming up with some marquee researchers, picking up say $50 million to $75 million dollars in a non-threatening minority equity investment that could take you to the next level.

Doug Giordano might have some thoughts on how that could work out.

The SVP of business development at the pharma giant has helped forge a new fund called the Pfizer Breakthrough Growth Initiative. And he has $500 million of Pfizer’s money to put behind 7 to 10 — or so — biotech stocks that fit that general description.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Bris­tol My­ers is clean­ing up the post-Cel­gene merg­er pipeline, and they’re sweep­ing out an ex­per­i­men­tal check­point in the process

Back during the lead up to the $74 billion buyout of Celgene, the big biotech’s leadership did a little housecleaning with a major pact it had forged with Jounce. Out went the $2.6 billion deal and a collaboration on ICOS and PD-1.

Celgene, though, also added a $530 million deal — $50 million up front — to get the worldwide rights to JTX-8064, a drug that targets the LILRB2 receptor on macrophages.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 83,200+ biopharma pros reading Endpoints daily — and it's free.

Mer­ck wins a third FDA nod for an­tibi­ot­ic; Mereo tack­les TIG­IT with $70M raise in hand

Merck — one of the last big pharma bastions in the beleaguered field of antibiotic drug development — on Friday said the FDA had signed off on using its combination drug, Recarbrio, with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. The drug could come handy for use in hospitalized patients who are afflicted with Covid-19, who carry a higher risk of contracting secondary bacterial infections. Once SARS-CoV-2, the virus behind Covid-19, infects the airways, it engages the immune system, giving other pathogens free rein to pillage and plunder as they please — the issue is particularly pertinent in patients on ventilators, which in any case are breeding grounds for infectious bacteria.

RA Cap­i­tal, Hill­house join $310M rush to back Ever­est's climb to com­mer­cial heights in Chi­na

Money has never been an issue for Everest Medicines. With an essentially open tab from their founders at C-Bridge Capital, the biotech has gone two and a half years racking up drug after drug, bringing in top exec after top exec, and issuing clinical update after update.

But now other investors want in — and they’re betting big.

Everest is closing its Series C at $310 million. The first $50 million comes from the Jiashan National Economic and Technological Development Zone; the remaining C-2 tranche was led by Janchor Partners, with RA Capital Management and Hillhouse Capital as co-leaders. Decheng Capital, GT Fund, Janus Henderson Investors, Rock Springs Capital, Octagon Investments all joined.